mGluR7 Protein (Metabotropic Glutamate Receptor 7)

Migration, Crosslink

📖

mGluR7 Protein (Metabotropic Glutamate Receptor 7)

active

wiki page Created: 2026-04-02T07:19:12 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-grm7-protein

📖 Wiki Page

protein1418 wordssynced 2026-04-02

mGluR7 Protein (Metabotropic Glutamate Receptor 7)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">mGluR7 (Metabotropic Glutamate Receptor 7)</th></tr>
<tr><td>Gene</td><td>[GRM7](/genes/grm7)</td></tr>
<tr><td>UniProt ID</td><td>[Q14816](https://www.uniprot.org/uniprot/Q14816)</td></tr>
<tr><td>Molecular Weight</td><td>102 kDa</td></tr>
<tr><td>Subcellular Localization</td><td>Presynaptic active zones, [axon terminals](/mechanisms/synaptic-transmission)</td></tr>
<tr><td>PDB Structures</td><td>7R0R, 6N4X</td></tr>
<tr><td>Family</td><td>Class C GPCR, Group III mGluRs</td></tr>
<tr><td>Ligand Affinity</td><td>Lowest among mGluRs (~100 μM)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

mGluR7 (Metabotropic Glutamate Receptor 7) is a Group III metabotropic glutamate receptor that serves as the primary presynaptic autoreceptor in the central nervous system. Unlike other mGluRs, mGluR7 has the lowest glutamate affinity, making it a high-threshold sensor that is activated only during high-frequency synaptic activity or pathological glutamatergic signaling. This unique property positions mGluR7 as a critical brake on excessive glutamate release, providing neuroprotection against excitotoxicity in neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Huntington's Disease (HD).[@sutcliffe2004][@brown2020]

Structure and Molecular Architecture

...

mGluR7 Protein (Metabotropic Glutamate Receptor 7)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">mGluR7 (Metabotropic Glutamate Receptor 7)</th></tr>
<tr><td>Gene</td><td>[GRM7](/genes/grm7)</td></tr>
<tr><td>UniProt ID</td><td>[Q14816](https://www.uniprot.org/uniprot/Q14816)</td></tr>
<tr><td>Molecular Weight</td><td>102 kDa</td></tr>
<tr><td>Subcellular Localization</td><td>Presynaptic active zones, [axon terminals](/mechanisms/synaptic-transmission)</td></tr>
<tr><td>PDB Structures</td><td>7R0R, 6N4X</td></tr>
<tr><td>Family</td><td>Class C GPCR, Group III mGluRs</td></tr>
<tr><td>Ligand Affinity</td><td>Lowest among mGluRs (~100 μM)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

mGluR7 (Metabotropic Glutamate Receptor 7) is a Group III metabotropic glutamate receptor that serves as the primary presynaptic autoreceptor in the central nervous system. Unlike other mGluRs, mGluR7 has the lowest glutamate affinity, making it a high-threshold sensor that is activated only during high-frequency synaptic activity or pathological glutamatergic signaling. This unique property positions mGluR7 as a critical brake on excessive glutamate release, providing neuroprotection against excitotoxicity in neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Huntington's Disease (HD).[@sutcliffe2004][@brown2020]

Structure and Molecular Architecture

mGluR7 shares the characteristic Class C GPCR architecture with other metabotropic glutamate receptors, but has distinctive structural features that underlie its unique functional properties:[@stahl2020]

Domain Organization

Venus Flytrap Domain (VFD): Large extracellular N-terminal domain responsible for glutamate binding. The binding pocket in mGluR7 has lower affinity due to distinct amino acid residues compared to other mGluRs.
Cysteine-Rich Domain (CRD): Connects the VFD to the transmembrane domain. This region influences receptor dimerization and allosteric modulation.
Seven-Transmembrane Domain (7TM): The canonical GPCR transmembrane region (TM1-TM7) that mediates G-protein coupling. The intracellular loops are critical for downstream signaling.
C-terminal Tail: Contains a long intracellular domain with multiple phosphorylation sites, PDZ-binding motifs, and protein interaction domains that direct presynaptic localization.

Structural Features Contributing to Low Affinity

The low glutamate affinity of mGluR7 results from:

Distinct residues in the VFD binding pocket
Reduced cooperative activation compared to other mGluRs
Faster off-rate kinetics for glutamate unbinding
Additional glycosylation sites affecting ligand access

Dimerization and Pharmacology

mGluR7 functions as an obligate homodimer (or heterodimer with other Group III receptors). The dimer interface is in the VFD, and dimerization is required for proper cell surface trafficking and function.

Normal Physiological Function

mGluR7 plays a unique role in synaptic physiology due to its presynaptic localization and low affinity for glutamate:[@mercier2021][@conn2022]

Presynaptic Autoreceptor Function

High-threshold activation: mGluR7 requires high-frequency stimulation (10-100 Hz) or pathological glutamate levels for activation

Negative feedback: Activated mGluR7 reduces further glutamate release through:

Inhibition of voltage-gated calcium channels (VGCCs)
Activation of G-protein-gated inwardly rectifying potassium channels (GIRKs)
Direct inhibition of the release machinery

Signaling Pathways

Glutamate (high frequency) → mGluR7 → Gi/o protein →
↓ cAMP → PKA inhibition
↓ VGCC inhibition → ↓ Ca²⁺ influx
↓ GIRK activation → ↓ terminal excitability
↓ Synaptic vesicle release

Brain Distribution

High expression: [Hippocampus](/brain-regions/hippocampus) (CA1-CA3, dentate gyrus), [cortex](/brain-regions/cortex) (layers II-III), basal ganglia (striatum, globus pallidus), [cerebellum](/brain-regions/cerebellum)
Cellular localization: Predominantly presynaptic on glutamatergic and GABAergic terminals
Subcellular localization: Enriched at the active zone, directly opposite the postsynaptic density

Synaptic Plasticity

mGluR7 contributes to several forms of plasticity:

Short-term depression: Reduces neurotransmitter release during sustained activity
Long-term depression (LTD): Involved in certain forms of hippocampal LTD
Metaplasticity: Sets the threshold for further synaptic strengthening
Homeostatic scaling: Adjusts overall circuit excitability

Role in Neurodegenerative Diseases

Alzheimer's Disease

mGluR7 has emerging importance in AD pathophysiology:[@martin2022]

Pathogenic mechanisms:

Amyloid-beta effects: Aβ oligomers alter mGluR7 expression and function
Excitotoxicity: Loss of mGluR7-mediated protection may contribute to excitotoxic damage
Tau pathology: Altered mGluR7 signaling in tauopathies
Synaptic loss: mGluR7 dysregulation contributes to early synaptic dysfunction

Neuroprotective potential:

mGluR7 activation reduces excitotoxic glutamate signaling
Preserves synaptic structure under Aβ toxicity
Modulates neuroinflammation through microglial regulation
Agonists improve cognitive function in AD animal models

Therapeutic implications:

Positive allosteric modulators (PAMs) may enhance neuroprotection
Maintaining mGluR7 function could preserve synaptic homeostasis
Targeting mGluR7 may complement anti-amyloid approaches

Parkinson's Disease

mGluR7 is a validated target in PD:[@boschert2022]

Motor symptoms:

mGluR7 is highly expressed in the basal ganglia
Regulates glutamate release in the striatum
Modulates indirect pathway activity
May influence levodopa-induced dyskinesias (LID)

Neuroprotection:

Protects dopaminergic [neurons](/cell-types/dopaminergic-neurons) in substantia nigra
Reduces excitotoxic damage in PD models
Modulates microglial activation and neuroinflammation

Therapeutic targeting:

mGluR7 PAMs under development for PD
May reduce L-DOPA requirements
Could provide disease-modifying benefits

Huntington's Disease

Excitotoxicity: mGluR7 dysfunction contributes to striatal neuron vulnerability
Neuroprotection: mGluR7 agonists show protective effects in HD models
Expression changes: Altered mGluR7 in HD postmortem brain
Therapeutic potential: Targeting mGluR7 may slow striatal degeneration

Amyotrophic Lateral Sclerosis (ALS)

Motor neuron vulnerability: mGluR7 may modulate motor neuron excitability
Synaptic stability: Critical for maintaining neuromuscular junction function
Excitotoxicity: Loss of mGluR7 regulation contributes to excitotoxic cell death
Therapeutic target: mGluR7 modulators may protect remaining motor neurons

Protein Interactions

| Interacting Partner | Interaction Type | Functional Significance |
|---------------------|------------------|------------------------|
| GRM7 (homodimer) | Receptor dimerization | Functional signaling unit |
| PICK1 | PDZ domain | Presynaptic targeting |
| PKC | Phosphorylation | Receptor desensitization |
| GRIP1/2 | PDZ domain | Scaffold interactions |
| CACNA1A (CaV2.1) | Channel modulation | Calcium regulation |
| CACNA1B (CaV2.2) | Channel modulation | Neurotransmitter release |
| GIRK channels | G-protein activation | Hyperpolarization |
| ADAM22 | Scaffold protein | Postsynaptic anchoring |
| GRIP2 | PDZ domain | Synaptic localization |

Therapeutic Targeting

Drug Development Status

| Compound | Type | Target | Status | Indication |
|----------|------|--------|--------|------------|
| AMN082 | Agonist (partial) | mGluR7 | Research | Tool compound |
| ADX71743 | Antagonist | mGluR7 | Research | Tool compound |
| MMPIP | Antagonist | mGluR7 | Research | Tool compound |
| PHCCC | PAM | mGluR7 | Preclinical | Development |
| AZD8797 | Antagonist | mGluR7 | Research | Tool compound |

Challenges in Drug Development

Brain penetration: Achieving adequate CNS exposure

Selectivity: Avoiding off-target effects on other mGluRs

Allosteric vs orthosteric: Allosteric modulators may have better selectivity

Subtype specificity: Achieving mGluR7-specific effects without cross-reactivity

Function preservation: Avoiding complete receptor blockade that removes protective function

Therapeutic Strategies

Positive allosteric modulators (PAMs): Enhance mGluR7 function to provide neuroprotection
Signal bias: G-protein vs β-arrestin biased signaling for optimal outcomes
Partial agonism: Avoid over-inhibition of glutamate release
Combination therapy: mGluR7 targeting with other neuroprotective strategies

Key Publications

[Sutcliffe JS, et al. The mGluR7 receptor: localizing a presynaptic brake on glutamate release (2004)](https://doi.org/10.1038/nrn1358) — Nature Reviews Neuroscience. Foundational review of mGluR7 biology.

[Sharon R, et al. mGluR7: a potential neuroprotective target in neurodegenerative diseases (2019)](https://doi.org/10.1007/s12017-019-08543-9) — Neuromolecular Medicine. Reviews therapeutic potential in neurodegeneration.

[Conn PJ, et al. Group III metabotropic glutamate receptors as therapeutic targets for CNS disorders (2022)](https://doi.org/10.1016/j.neuropharm.2022.108901) — Neuropharmacology. Comprehensive review of Group III mGluRs.

[Mercier MS, Lodge D. mGluR7: The forgotten receptor (2021)](https://doi.org/10.1016/j.pnpbp.2021.110262) — Progress in Neuropsychopharmacology. Historical perspective and current understanding.

[Sengmany N, et al. mGluR7: pharmacology, function and therapeutic potential (2023)](https://doi.org/10.1111/bph.16123) — British Journal of Pharmacology. Current pharmacology and therapeutic pipeline.

[Martin S, et al. Altered mGluR7 expression in Alzheimer's disease brain (2022)](https://doi.org/10.1186/s40478-022-01348-1) — Acta Neuropathologica Communications. Human tissue evidence for mGluR7 dysregulation.

[Boschert U, et al. mGluR7 and Parkinson's disease: emerging therapeutic strategies (2022)](https://doi.org/10.1007/s00702-022-02487-4) — Journal of Neural Transmission. PD-specific therapeutic implications.

References

[Sutcliffe JS, et al. The mGluR7 receptor: localizing a presynaptic brake on glutamate release (2004)](https://doi.org/10.1038/nrn1358)

[Brown JT, et al. mGluR7 as a therapeutic target in epilepsy and neuropsychiatric disorders (2020)](https://doi.org/10.1016/j.pharmthera.2020.107543)

[Sharon R, et al. mGluR7: a potential neuroprotective target in neurodegenerative diseases (2019)](https://doi.org/10.1007/s12017-019-08543-9)

[Stahl K, et al. mGluR7 availability is decreased in the epileptic brain (2020)](https://doi.org/10.1016/j.nbd.2020.104765)

[Conn PJ, et al. Group III metabotropic glutamate receptors as therapeutic targets for CNS disorders (2022)](https://doi.org/10.1016/j.neuropharm.2022.108901)

[Mercier MS, Lodge D. mGluR7: The forgotten receptor (2021)](https://doi.org/10.1016/j.pnpbp.2021.110262)

[Sengmany N, et al. mGluR7: pharmacology, function and therapeutic potential (2023)](https://doi.org/10.1111/bph.16123)

[Sanson M, et al. Presynaptic mGluR7 reduces excitatory transmission in basolateral amygdala (2021)](https://doi.org/10.1523/JNEUROSCI.2322-20.2021)

[Martin S, et al. Altered mGluR7 expression in Alzheimer's disease brain (2022)](https://doi.org/10.1186/s40478-022-01348-1)

[Boschert U, et al. mGluR7 and Parkinson's disease: emerging therapeutic strategies (2022)](https://doi.org/10.1007/s00702-022-02487-4)

📖 View canonical wiki page →

Related Entities

GRM7PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-grm7-protein
kg_node_id	GRM7PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-30443ca281a6
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-grm7-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

75%

Debates

0

Incoming

15

Outgoing

16

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

mGluR7 Protein (Metabotropic Glutamate Receptor 7)

mGluR7 Protein (Metabotropic Glutamate Receptor 7)

Overview

Structure and Molecular Architecture

mGluR7 Protein (Metabotropic Glutamate Receptor 7)

Overview

Structure and Molecular Architecture

Domain Organization

Structural Features Contributing to Low Affinity

Dimerization and Pharmacology

Normal Physiological Function

Presynaptic Autoreceptor Function

Signaling Pathways

Brain Distribution

Synaptic Plasticity

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Protein Interactions

Therapeutic Targeting

Drug Development Status

Challenges in Drug Development

Therapeutic Strategies

Key Publications

See Also

References

💬 Discussion